Safety, Tolerability and Pharmacokinetics of Etelcalcetide in Hemodialysis Patients With Secondary Hyperparathyroidism
Completed
KAI Pharmaceuticals
Phase 1
2010-09-07
The purpose of this study is to characterize the safety and tolerability of single rising
doses of etelcalcetide in hemodialysis patients with secondary hyperparathyroidism.
Safety, Tolerability and Efficacy of Etelcalcetide in Hemodialysis Patients With Secondary Hyperparathyroidism
Completed
KAI Pharmaceuticals
Phase 2
2011-02-20
The purpose of this study is to characterize the safety and tolerability and efficacy of
multiple ascending doses of etelcalcetide in hemodialysis patients for the treatment of
secondary hyperparathyroidism (HPT).
Etelcalcetide to Treat Secondary Hyperparathyroidism in Hemodialysis Patients With Chronic Kidney Disease-Mineral and Bone Disorder
Completed
KAI Pharmaceuticals
Phase 2
2011-12-05
The purpose of this study is to evaluate the effect of thrice weekly intravenous (IV)
administration of etelcalcetide in the treatment of secondary hyperparathyroidism (SHPT) in
hemodialysis patients with chronic kidney disease-mineral and bone disorder (CKD-MBD).
Open-label Study to Assess the Long-term Safety and Efficacy of Etelcalcetide (Also Known as AMG 416 or KAI-4169) in Patients With Secondary Hyperparathyroidism
Terminated
KAI Pharmaceuticals
Phase 2
2012-03-01
The purpose of this study is to evaluate the long term safety and efficacy of thrice weekly
intravenous (IV) administration of etelcalcetide in the treatment of secondary
hyperparathyroidism (SHPT) in patients receiving hemodialysis who had completed 12 weeks of
treatment with etelcalcetide in parent study 20120331 (KAI-4169-005; NCT01414114).
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
